Evidence map›Paper›PMID 41323213›Full record

ArticlePhysics and imaging in radiation oncology2025

A multi-institutional dummy run on segmentation variability and plan quality of stereotactic body radiotherapy for oligometastatic disease.

Hideaki Hirashima, Yukinori Matsuo, Satoshi Ishikura, Mitsuhiro Nakamura, Ikuno Nishibuchi, Daisuke Kawahara, Yoshihisa Shimada, Yoshiro Nakahara, Teiji Nishio, Naoto Shikama and 6 more

Abstract read
In one paragraph

Article in Physics and imaging in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Hideaki HirashimaDepartment of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
Yukinori MatsuoDepartment of Radiation Oncology, Kindai University Faculty of Medicine, Osaka 589-8511, Japan.
Satoshi IshikuraDepartment of Radiation Oncology, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan.
Mitsuhiro NakamuraDepartment of Advanced Medical Physics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Ikuno NishibuchiDepartment of Radiation Oncology, Graduate School of Biomedical Health Sciences, Hiroshima University, Hiroshima, Japan.
Daisuke KawaharaDepartment of Radiation Oncology, Graduate School of Biomedical Health Sciences, Hiroshima University, Hiroshima, Japan.
Yoshihisa ShimadaDepartment of Surgery, Tokyo Medical University, Tokyo, Japan.
Yoshiro NakaharaDepartment of Respiratory Medicine, Kitasato University Hospital, Kanagawa, Japan.
Teiji NishioMedical Physics Laboratory, Division of Health Science, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
Naoto ShikamaDepartment of Radiation Oncology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Shun-Ichi WatanabeDepartment of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan.
Isamu OkamotoDepartment of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Toshiyuki IshibaDepartment of Breast Surgery, Institute of Science Tokyo, Tokyo, Japan.
Fumikata HaraDepartment of Breast Oncology, Aichi Cancer Center Hospital, Nagoya City, Japan.
Tadahiko ShienDepartment of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan.
Takashi MizowakiDepartment of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: Oligometastatic disease represents limited metastatic burden, and local ablative therapies such as stereotactic body radiotherapy (SBRT) may improve survival. However, inter-institutional variability in target segmentation and treatment planning can compromise treatment quality. This study aimed to evaluate the segmentation variability and dose distribution quality of SBRT in oligometastatic settings using a multi-institutional dummy run approach. Methods and materials: Sixty-nine institutions were provided with two anonymized cases of adrenal and spine metastases to delineate targets and organs at risk (OARs) and create intensity-modulated radiotherapy plans following a protocol. Variability was quantified using the Dice similarity coefficient (DSC), Hausdorff distance, and mean distance to agreement. Plan qualities were assessed using the Paddick conformity index, modified gradient index, and a new three-dimensional conformity-gradient index (3D-CGI). Knowledge-based planning (KBP) was applied to explore potential improvements in OAR sparing. Results: All submitted plans met protocol dose constraints. However, substantial segmentation variability was observed, particularly for the spine case. Among 136 plans, 79% demonstrated acceptable conformity and dose gradients, with 3D-CGI < 6 correlating with favorable distributions. Mean DSC was 0.93 for the clinical target volume and 0.76 for the cauda equina, which showed the highest variability. KBP reduced OAR doses for the adrenal case but showed limited impact for the spine case. Conclusions: Although dose constraints were achieved, segmentation variability remained substantial, particularly for the cauda equina in the spine case. These findings emphasize inter-institutional differences and the need for standardization and tools to improve SBRT consistency.

Indexed as

Dose distribution accuracyDummy runOligometastatic diseaseSegmentation variability

Identifiers

PMID41323213
PMCPMC12664400

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.